Peer-Led HIV Prevention Beats Clinics for Young People, Trials Find

Peer-Led HIV Prevention outperformed standard clinic delivery in two major trials among adolescents and young adults in rural South Africa, with trained young navigators lifting uptake of HIV prevention well above what ordinary primary care achieved and most participants choosing a long-acting injectable shot over daily pills, according to the university's reporting on the two trials.

The findings land at a moment when HIV prevention is changing fast. Injectable options that protect for months are moving from trial settings into national rollouts across Africa, and health officials are wrestling with a familiar problem: the medicines work, but only if young people can actually get them. The new trial results suggest the messenger may matter as much as the medicine.

Two trials, one big shift

The work was led by researchers at the UCL Institute for Global Health together with the Africa Health Research Institute, and it focused on adolescents and young adults, the age group where new HIV acquisitions remain stubbornly high. The first study, known as Thetha Nami, tested what happens when trained peer navigators actively mobilise young people into community-based sexual health services instead of leaving them to find their way through standard primary care clinics.

The difference was substantial. Young people reached by peer navigators took up risk-informed HIV prevention at a rate nearly double that of those relying on standard care, the researchers reported, and the peer-led approach also increased contraception use and uptake of pre-exposure prophylaxis. The second trial, LAPIS, built on that model by adding something extra: a real choice of prevention methods, including daily oral pills and a long-acting injectable shot called CAB-LA.

Choice changed the picture again. Compared with peer-led delivery of oral pills alone, offering the menu of options raised uptake of prevention medicines by more than twofold and improved retention in care by about a third, according to the trial data. Nearly two-thirds of participants picked the long-acting shot, a striking signal that daily pill-taking was the weak link all along.

Why the shot keeps beating the pill

That preference echoes across the continent right now. In Zambia, where young people account for more than a third of new HIV infections, health authorities have begun rolling out lenacapavir, another long-acting injectable, with plans to reach tens of thousands of people through hundreds of health facilities by the end of next year. The parallel is not accidental: adolescents, and young women in particular, keep telling services the same thing. A discreet injection taken a few times a year fits real life in a way that a bottle of pills on a bedroom shelf often does not.

"The introduction of lenacapavir gives us an opportunity to build on that progress and ensure that prevention reaches the people who need it most, particularly adolescent girls and young women," said the UNAIDS regional director for Eastern and Southern Africa, welcoming the Zambia rollout of a long-acting injectable. Globally, more than a million people still newly acquired HIV in 2025, and only about half of children living with the virus are receiving treatment, compared with roughly four in five adults, figures from the UN agency show.

The honest caveat

The trial teams are not claiming victory. Neither study reduced the overall prevalence of transmissible HIV in the communities, and the researchers point to two stubborn reasons: many young people struggled to stay on daily oral pills, and too few of those living with the virus were virally suppressed, which kept transmission chains alive. In other words, getting prevention into hands is necessary but not sufficient when the broader treatment picture stays uneven.

There is a policy warning tucked into the results too. The findings arrived as some health systems are pulling back from community-based delivery models toward clinic-only services. The trial evidence argues in the opposite direction: trained peers, working in neighborhoods rather than waiting rooms, reached young people the clinics were missing, and Peer-Led HIV Prevention is one of the clearest proofs yet that delivery design decides outcomes. For readers, the takeaway is practical. If you are a young person anywhere weighing HIV prevention, the menu of options is wider than it was five years ago, and the new data says that how you are offered those options — by someone who speaks your language, near where you live — can matter as much as what is in the syringe or the pill bottle.

For more on how infectious-disease medicine is changing, read about the first functional hepatitis B cure to win FDA approval and the cell therapy that shrank eye cancer tumors in every patient, plus new brain-scan research on junk food.